Cipla clarifies on promoter stake sale; for personal and philanthropic purposes

Drugmaker Cipla has said that its promoters Dr Y K Hamied, Chairman and MK Hamied, Vice Chairman who are Non-Executive Directors, have sold 2.5 percent stake in the company for “personal purposes including philanthropy”.

According to reports, the sale would bring in about Rs 1800-odd crore.

In a clarification to the Bombay Stock Exchange, a note quoting Samina Hamied, Cipla’s Executive Vice Chairperson said, 2,01,69,756 shares (representing 2.5 percent of the total issued and paid-up share capital of the company) had been sold today.

Post transaction, the promoter group will continue to hold 34.23 percent in the company, the note said, adding that they remain fully committed and invested in the future of Cipla Limited. “The senior promoters who are both in their eighties, intend to use the funds generated from this sale for personal purposes including philanthropy. The promoter group does not plan to sell any further shares in the foreseeable future,” the note said.

“Cipla is being led by the third generation of the founding family. As a family, we are fully committed to the organisation. I will continue to carry forward the Cipla legacy and drive the company into the future – to achieve new goals and scale new heights,” the note from Samina, daughter of MK Hamied said.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’